基蛋生物(603387.SH):3名股東減持時間過半 累計減持259.816萬股
格隆匯12月12日丨基蛋生物(603387.SH)公佈,公司股東蘇州捷富投資企業(有限合夥)、杭州維思捷朗股權投資合夥企業(有限合夥)和杭州維思投資合夥企業(有限合夥)的減持股份計劃公告日至本公告日期間,公司因回購註銷限制性股票3.76萬股,股份總額由260,417,703股變更為260,380,071股。以下持股比例、減持比例均按照公司當前總股本260,380,071股計算。
截止本公告披露日,捷富投資、杭州捷朗和杭州維思於2019年9月13日至2019年12月11日通過集合競價交易方式累計減持了259.816萬股,約佔公司總股本的0.9978%。捷富投資、杭州捷朗和杭州維思本次減持時間過半,本次計劃尚餘261.0193萬股未完成。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.